Yi-Qi-Zeng-Min-Tang, a Chinese medicine, ameliorates insulin resistance in type 2 diabetic rats

doi:10.3748/wjg.v17.i8.987

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3733)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

367

HTML

2975

Figures (1-3)

244

Tables (1-4)

147

Sum=3733

Feb 28, 2011 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Feb 28, 2011; 17(8): 987-995
Published online Feb 28, 2011. doi: 10.3748/wjg.v17.i8.987

Table 1 Composition of Yi-Qi-Zeng-Min-Tang

Component	Part used	Amount used (%)
Radix Astragali	Root	16.0
Mung bean coating	Seed bark	16.0
Folium Perillae	Leaf	10.6
Phellodendron amurense Rupr.	Bark	10.6
Pollen Typhae	Pollen	10.6
Serissa foetida	Whole strain	10.6
Ramulus Cinnamomi	Twig	6.4
Radix Aconiti Lateralis Preparata	Prepared root	6.4
Coptis Chinensis Franch	Root	6.4
Rhizoma Alismatis	Tuberous stem	6.4

Table 2 General characteristics of normal pellet diet-fed rats and high fat diet-fed/streptozotocin induced diabetic rats (mean ± SE)

	NPD (n = 10)	HFD+STZ (n = 50)
Body weight (g)	411.30 ± 2.74	457.90 ± 2.43^b
Glu (mmol/L)	3.60 ± 0.31	12.82 ± 1.08^b
FINS (pg/mL)	4820.49 ± 326.89	7197.36 ± 253.89^b
HOMA-IR	18.74 ± 1.56	97.26 ± 4.98^b
TG (mmol/L)	0.78 ± 0.05	2.24 ± 0.12^b
TC (mmol/L)	2.14 ± 0.06	8.40 ± 0.49^b
HDL-c (mmol/L)	1.27 ± 0.03	0.57 ± 0.03^b
LDL-c (mmol/L)	0.72 ± 0.04	7.84 ± 0.51^b

Glu: Fasting serum glucose; FINS: Fasting serum insulin; HOMA-IR: Homeostasis model assessment of basal insulin resistance; TG: Triglyceride; TC: Total cholesterol; HDL-c: High-density lipoprotein cholesterol; LDL-c: Low-density lipoprotein cholesterol; NPD: Normal pellet diet; HFD: High fat diet; STZ: Streptozotocin.

^bP < 0.01 vs NPD group.

Table 3 General characteristics of diabetic rats after 4 wk of treatment (mean ± SE)

	CON (n = 10)	MOD (n = 10)	LDY (n = 10)	MDY (n = 10)	HDY (n = 10)	ROS (n = 10)
Body weight (g)	496.20 ± 13.40	418.08 ± 16.06^b	434.80 ± 13.15^b	433.75 ± 10.99^b	443.14 ± 13.15^a	439.30 ± 15.27^b
Glu (mmol/L)	3.95 ± 0.27	18.40 ± 1.63^b	17.57 ± 0.86^b	14.35 ± 1.60^b^c	13.20 ± 0.64^b^d	13.00 ± 1.29^b^d
FINS (pg/mL)	3866.43 ± 249.23	9553.83 ± 899.22^b	7170.76 ± 739.99^b	7228.81 ± 480.47^a	7114.41 ± 762.97^a	8363.51 ± 564.91^b
HOMA-IR	16.02 ± 1.16	191.49 ± 28.32^b	133.39 ± 13.41^b	99.67 ± 12.97^b^c	98.99 ± 12.40^b^c	107.66 ± 13.01^b^c
TG (mmol/L)	1.38 ± 0.13	2.99 ± 0.56^b	2.91 ± 0.47^b	2.62 ± 0.44^a	2.58 ± 0.77	2.46 ± 0.31^a
TC (mmol/L)	2.06 ± 0.11	8.06 ± 0.69^b	8.08 ± 0.80^b	6.49 ± 1.40^b	5.45 ± 0.64^b^c	7.79 ± 0.78^b
HDL-c (mmol/L)	1.02 ± 0.04	0.61 ± 0.08^b	0.71 ± 0.07^a	0.82 ± 0.07	0.87 ± 0.11^c	0.84 ± 0.11
LDL-c (mmol/L)	1.04 ± 0.08	7.46 ± 0.75^b	7.37 ± 0.82^b	5.67 ± 1.40^b	4.58 ± 0.70^b^d	6.95 ± 0.85^b

Glu: Fasting serum glucose; FINS: Fasting serum insulin; HOMA-IR: Homeostasis model assessment of basal insulin resistance; TG: Triglyceride; TC: Total cholesterol; HDL-c: High-density lipoprotein cholesterol; LDL-c: Low-density lipoprotein cholesterol; CON: Control group; MOD: Type 2 diabetes model group; LDY: Low-dose Yi-Qi-Zeng-Min-Tang (YQZMT) group; MDY: Medium-dose YQZMT group; HDY: High-dose YQZMT group; ROS: Rosiglitazone group.

^aP < 0.05,

^bP < 0.01 vs CON group;

^cP < 0.05,

^dP < 0.01 vs MOD group.

Table 4 General characteristics of diabetic rats after 8 wk of treatment (mean ± SE)

	CON (n = 10)	MOD (n = 10)	LDY (n = 10)	MDY (n = 10)	HDY (n = 10)	ROS (n = 10)
Body weight (g)	562.73 ± 12.17	424.15 ± 18.30^b	412.60 ± 12.89^b	444.88 ± 12.02^b	445.71 ± 15.54^b	470.80 ± 19.9^b^c
Glu (mmol/L)	3.85 ± 0.33	17.65 ± 2.22^b	14.48 ± 0.68^b	12.76 ± 0.56^b^d	12.16 ± 1.00^b^d	12.70 ± 0.55^b^d
FINS (pg/mL)	3863.25 ± 316.14	1973.70 ± 237.35^a	3025.17 ± 296.30	2275.06 ± 256.45	1815.21 ± 187.26^a	2087.53 ± 220.78^a
HOMA-IR	16.59 ± 2.65	38.79 ± 9.02^b	48.48 ± 4.74^b	30.37 ± 3.57	22.68 ± 2.37^c	21.66 ± 2.13^c
TG (mmol/L)	0.83 ± 0.15	1.99 ± 0.26^b	1.88 ± 0.31^b	1.19 ± 0.16^c	0.87 ± 0.15^d	1.05 ± 0.16^d
TC (mmol/L)	1.56 ± 0.15	6.50 ± 1.04^b	5.80 ± 0.66^b	4.51 ± 0.76^b	3.31 ± 0.52^b^d	4.71 ± 0.51^b
HDL-c (mmol/L)	1.06 ± 0.14	0.50 ± 0.03^b	0.69 ± 0.05^b	0.78 ± 0.04^d	0.84 ± 0.08^d	0.97 ± 0.08^d
LDL-c (mmol/L)	0.50 ± 0.05	6.00 ± 1.07^b	5.11 ± 0.67^b	3.73 ± 0.50^b	2.47 ± 0.50^b^d	3.74 ± 0.49^b

Glu: Fasting serum glucose; FINS: Fasting serum insulin; HOMA-IR: Homeostasis model assessment of basal insulin resistance; TG: Triglyceride; TC: Total cholesterol; HDL-c: High-density lipoprotein cholesterol; LDL-c: Low-density lipoprotein cholesterol; CON: Control group; MOD: Type 2 diabetes model group; LDY: Low-dose Yi-Qi-Zeng-Min-Tang (YQZMT) group; MDY: Medium-dose YQZMT group; HDY: High-dose YQZMT group; ROS: Rosiglitazone group.

^aP < 0.05,

^bP < 0.01 vs CON group;

^cP < 0.05,

^dP < 0.01 vs MOD group.

Citation: Zhang Z, Xue HL, Liu Y, Wang WJ. Yi-Qi-Zeng-Min-Tang, a Chinese medicine, ameliorates insulin resistance in type 2 diabetic rats. World J Gastroenterol 2011; 17(8): 987-995
URL: https://www.wjgnet.com/1007-9327/full/v17/i8/987.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i8.987